Q-omics provides the consensus-scored SLC1A6 profile across patient tissues and cancer cell-line models. SLC1A6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SLC1A6 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, SLC1A6 protein abundance shows 11,536 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, BLCA, and GBM as cancer lineages where SLC1A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC1A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC1A6 survival associations across molecular data types. SLC1A6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC1A6 RNA expression–survival associations across cancer types. High SLC1A6 expression shows unfavorable associations in OV, BRCA, COAD, LIHC and BLCA, but favorable associations in LGG. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for SLC1A6 RNA expression.
This table summarizes SLC1A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC1A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC1A6 shows lower tumor expression in KICH, KIRC and PRAD and higher tumor expression in BLCA, LUSC and BRCA. The BLCA box plot shows higher SLC1A6 RNA expression in tumor versus normal tissue (log2 FC = +5.314, t-test p < 0.001).
This table shows molecular features associated with SLC1A6 in patient tissues and cancer cell lines. In patient samples, SLC1A6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC1A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
